BetterLife Pharma Inc. (BETRF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 3.24 Million CAD | -65.0% |
| 2023 | 9.25 Million CAD | -7.14% |
| 2022 | 9.96 Million CAD | 25.33% |
| 2021 | 7.95 Million CAD | -13.52% |
| 2020 | 9.19 Million CAD | 42.4% |
| 2019 | 6.45 Million CAD | 457.56% |
| 2018 | 1.15 Million CAD | -84.83% |
| 2017 | 7.63 Million CAD | -36.3% |
| 2016 | 11.99 Million CAD | 16583.09% |
| 2015 | 71.87 Thousand CAD | 56.74% |
| 2014 | 45.85 Thousand CAD | -48.87% |
| 2013 | 89.69 Thousand CAD | -75.01% |
| 2012 | 358.97 Thousand CAD | 152.4% |
| 2011 | 142.22 Thousand CAD | 19.55% |
| 2010 | 118.96 Thousand CAD | -22.37% |
| 2009 | 153.23 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 3.2 Million CAD | -65.33% |
| 2024 Q3 | 698.62 Thousand CAD | -31.14% |
| 2024 Q1 | 766.44 Thousand CAD | -5.1% |
| 2024 Q4 | 730.24 Thousand CAD | 4.53% |
| 2024 Q2 | 1.01 Million CAD | 32.37% |
| 2023 Q2 | 1.21 Million CAD | -59.95% |
| 2023 Q1 | 3.02 Million CAD | 41.76% |
| 2023 Q4 | 807.65 Thousand CAD | -81.42% |
| 2023 Q3 | 4.34 Million CAD | 259.14% |
| 2023 FY | 9.25 Million CAD | -7.14% |
| 2022 Q3 | 2.1 Million CAD | -37.35% |
| 2022 FY | 9.96 Million CAD | 25.33% |
| 2022 Q2 | 3.36 Million CAD | 41.74% |
| 2022 Q1 | 2.37 Million CAD | 2.67% |
| 2022 Q4 | 2.13 Million CAD | 1.22% |
| 2021 Q3 | 2.79 Million CAD | 85.23% |
| 2021 FY | 7.95 Million CAD | -13.52% |
| 2021 Q1 | 1.14 Million CAD | 2.74% |
| 2021 Q2 | 1.5 Million CAD | 31.21% |
| 2021 Q4 | 2.3 Million CAD | -17.33% |
| 2020 Q3 | 2.3 Million CAD | -43.76% |
| 2020 Q2 | 4.09 Million CAD | 144.51% |
| 2020 Q1 | 1.67 Million CAD | 34.48% |
| 2020 FY | 9.19 Million CAD | 42.4% |
| 2020 Q4 | 1.11 Million CAD | -51.4% |
| 2019 Q4 | 1.24 Million CAD | -31.3% |
| 2019 Q2 | 1.51 Million CAD | -17.93% |
| 2019 Q3 | 1.81 Million CAD | 19.9% |
| 2019 Q1 | 1.84 Million CAD | 402.86% |
| 2019 FY | 6.45 Million CAD | 457.56% |
| 2018 Q2 | 319.47 Thousand CAD | 8.7% |
| 2018 FY | 1.15 Million CAD | -84.83% |
| 2018 Q4 | 366.17 Thousand CAD | 95.64% |
| 2018 Q3 | 187.17 Thousand CAD | -41.41% |
| 2018 Q1 | 293.9 Thousand CAD | -65.25% |
| 2017 FY | 7.63 Million CAD | -36.3% |
| 2017 Q1 | 4.16 Million CAD | -45.21% |
| 2017 Q4 | 845.68 Thousand CAD | 0.12% |
| 2017 Q2 | 1.45 Million CAD | -64.99% |
| 2017 Q3 | 844.7 Thousand CAD | -42.07% |
| 2016 Q4 | 7.6 Million CAD | 166121.71% |
| 2016 FY | 11.99 Million CAD | 16583.09% |
| 2016 Q1 | 1.44 Million CAD | 10285.68% |
| 2016 Q2 | 2.94 Million CAD | 103.45% |
| 2016 Q3 | 4573.00 CAD | -99.84% |
| 2015 Q3 | 16.65 Thousand CAD | -44.18% |
| 2015 FY | 71.87 Thousand CAD | 56.74% |
| 2015 Q1 | 11.46 Thousand CAD | 215.95% |
| 2015 Q2 | 29.84 Thousand CAD | 160.36% |
| 2015 Q4 | 13.91 Thousand CAD | -16.47% |
| 2014 Q2 | 27.31 Thousand CAD | 140.33% |
| 2014 Q4 | -9885.00 CAD | -157.92% |
| 2014 Q3 | 17.06 Thousand CAD | -37.51% |
| 2014 Q1 | 11.36 Thousand CAD | 392.28% |
| 2014 FY | 45.85 Thousand CAD | -48.87% |
| 2013 Q2 | 31.59 Thousand CAD | -14.62% |
| 2013 FY | 89.69 Thousand CAD | -75.01% |
| 2013 Q1 | 37 Thousand CAD | 187.82% |
| 2013 Q3 | 24.97 Thousand CAD | -20.96% |
| 2013 Q4 | -3888.00 CAD | -115.57% |
| 2012 Q3 | 154.36 Thousand CAD | 110.45% |
| 2012 Q2 | 73.35 Thousand CAD | -58.69% |
| 2012 FY | 358.97 Thousand CAD | 152.4% |
| 2012 Q4 | -42.14 Thousand CAD | -127.3% |
| 2012 Q1 | 177.57 Thousand CAD | 238.45% |
| 2011 Q2 | 42.52 Thousand CAD | 57.19% |
| 2011 Q4 | 52.46 Thousand CAD | 159.92% |
| 2011 Q3 | 20.18 Thousand CAD | -52.53% |
| 2011 FY | 142.22 Thousand CAD | 19.55% |
| 2011 Q1 | 27.05 Thousand CAD | 68.16% |
| 2010 Q4 | 16.08 Thousand CAD | 13.96% |
| 2010 Q2 | 75.96 Thousand CAD | 493.3% |
| 2010 FY | 118.96 Thousand CAD | -22.37% |
| 2010 Q3 | 14.11 Thousand CAD | -81.42% |
| 2010 Q1 | 12.8 Thousand CAD | 0.0% |
| 2009 FY | 153.23 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.266% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 34.113% |
| SQZ Biotechnologies Company | 85.61 Million USD | 96.216% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 89.036% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 91.303% |
| Mesoblast Limited | 5.9 Million USD | 45.099% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -115.743% |
| Genus plc | 147.7 Million USD | 97.806% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 63.092% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -141.531% |
| Marizyme, Inc. | 19.23 Million USD | 83.159% |
| ContraFect Corporation | 56.88 Million USD | 94.304% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 61.144% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 26.503% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -119.12% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -11.11% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -16.123% |
| MultiCell Technologies, Inc. | 567.42 USD | -570948.077% |
| Accustem Sciences Inc. | 3.74 Million USD | 13.511% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 96.23% |
| EV Biologics, Inc. | 531.96 Thousand USD | -509.111% |
| Q BioMed Inc. | 3.43 Million USD | 5.715% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 86.89% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -731.757% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -23.319% |
| Biomind Labs Inc. | 994.18 Thousand USD | -225.92% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 98.563% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 51.768% |
| Skye Bioscience, Inc. | 13.54 Million USD | 76.082% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -58.16% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 13060.964% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 35.736% |
| IMV Inc. | 37.7 Million USD | 91.407% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 79.761% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -76.571% |
| GB Sciences, Inc. | 1.42 Million USD | -128.104% |
| Alpha Cognition Inc. | 9.7 Million USD | 66.615% |
| HST Global, Inc. | 140.9 Thousand USD | -2199.56% |
| CSL Limited | 3.44 Billion USD | 99.906% |
| Halberd Corporation | 74.84 Thousand USD | -4229.442% |
| Enzolytics Inc. | 2.17 Million USD | -48.669% |
| Resverlogix Corp. | 12.71 Million USD | 74.51% |
| Affymax, Inc. | 39.38 Million USD | 91.773% |
| SYBLEU INC | 160.87 Thousand USD | -1914.123% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 11.243% |
| argenx SE | 1.53 Billion USD | 99.789% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 94.359% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -210.368% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -105.162% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 4.838% |
| AVAX Technologies, Inc. | 7.31 Million USD | 55.675% |
| Zenith Capital Corp. | 8.94 Million USD | 63.768% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.607% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -18499.627% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -31.968% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1789.254% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.738% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -84.138% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -64.31% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -73.798% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 70.183% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -68.683% |
| BioStem Technologies, Inc. | 22.97 Million USD | 85.897% |
| ONE Bio Corp. | 6.44 Million USD | 49.716% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1685.404% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -142.636% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -188.044% |
| Agentix Corp. | 1.37 Million USD | -136.211% |
| LadRx Corporation | 3.81 Million USD | 14.994% |
| Cell Source, Inc. | 4.32 Million USD | 25.087% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -679.881% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -250.861% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -250.861% |
| NovAccess Global Inc. | 2.46 Million USD | -31.356% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -34.733% |
| Itoco Inc. | 919.14 Thousand USD | -252.528% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 23.551% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -189.566% |
| Kadimastem Ltd | 2.41 Million USD | -34.444% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1138.028% |
| CytoDyn Inc. | 18.05 Million USD | 82.056% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -12773.936% |
| Mobile Lads Corp. | 554.54 Thousand USD | -484.305% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1372.315% |
| Qrons Inc. | 643.67 Thousand USD | -403.395% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -128.219% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -45.31% |
| Rebus Holdings, Inc. | 664 Thousand USD | -387.988% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -78.396% |
| International Stem Cell Corporation | 5.27 Million USD | 38.527% |
| Bioxytran, Inc. | 3.82 Million USD | 15.18% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -6055.239% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -15828.039% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 91.065% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -100.262% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -340.349% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -4.154% |
| Neutra Corp. | 243.82 Thousand USD | -1228.943% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 81.439% |
| PureTech Health plc | 144.59 Million USD | 97.759% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 84.186% |
| IXICO plc | 4.7 Million USD | 31.161% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 63.167% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.248% |
| CSL Limited | 3.89 Billion USD | 99.917% |
| Cellectis S.A. | 97.32 Million USD | 96.671% |